Sanxin Medical: Summary of 2026 Semi-Annual Report
Summary of the 2026 Semi-Annual Report of Jiangxi Sanxin Medical Technology Co., Ltd.
Securities code: 300453 Securities abbreviation: Sanxin Medical Announcement number: 2026-056
Bond code: 123280 Bond abbreviation: Sanxin Convertible Bonds
Jiangxi Sanxin Medical Technology Co., Ltd.
2026 Interim Report Summary
1. Important tips
This summary of the semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should read the full text of the semi-annual report carefully in the media designated by the China Securities Regulatory Commission.
All directors have attended the board meeting where this report was considered.
Non-standard audit opinion tips
□Applicable Not applicable
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital reviewed by the board of directors
Applicable □Not applicable
Whether to convert public reserve funds into share capital?
□Yes No
The company's profit distribution plan reviewed and approved by the board of directors is as follows: based on 521,924,275 shares (after deducting 160,000 shares in the company's special securities account for repurchase), a cash dividend of 1 yuan (including tax) will be distributed to all shareholders for every 10 shares, and 0 bonus shares (including tax) will be given. The reserve fund will not be converted into share capital. Preferred stock profit distribution plan for the reporting period approved by the board of directors
□Applicable Not applicable
2. Basic situation of the company
- Company profile
Stock abbreviation Sanxin Medical Stock Code 300453 Stock Exchange Shenzhen Stock Exchange
Contact person and contact information Secretary of the Board of Directors Name of securities affairs representative Liu Ming Ye Meilian
Phone 0791-85950380 0791-85950380
Office address No. 4899, Hezhou Road, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province No. 4899, Hezhou Road, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province E-mail [email protected] [email protected]
Summary of the 2026 Semi-Annual Report of Jiangxi Sanxin Medical Technology Co., Ltd.
- Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
This reporting period Same period last year This reporting period increased or decreased operating income compared with the same period last year (yuan) 836,722,599.37 760,807,967.78 9.98% Net profit attributable to shareholders of listed companies (yuan) 132,115,861.37 115,118,078.10 14.77% Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses
121,609,218.46 103,229,980.04 17.80% net profit (yuan)
Net cash flow generated from operating activities (yuan) 155,494,840.30 189,193,541.41 -17.81% Basic earnings per share (yuan/share) 0.2535 0.2207 14.86% Diluted earnings per share (yuan/share) 0.2535 0.2204 15.02% Weighted average return on equity 8.65% 8.35% 0.30%
End of the reporting period End of the previous year Total assets increased or decreased at the end of the reporting period compared with the end of the previous year (yuan) 2,465,188,191.06 2,428,885,839.81 1.49% Net assets attributable to shareholders of listed companies (yuan) 1,493,271,762.93 1,458,293,542.45 2.40%
- Number of shareholders and shareholding status of the company
Unit: Share
Priority for restoration of voting rights at the end of the reporting period Shares with special voting rights
Total number of common shareholders at the end of the reporting period 18,601 0 Total number of 0 shareholders (if any) Total number of shareholders (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Pledge, marking or freezing situation Name of shareholder Nature of shareholder Shareholding ratio Number of shares held Number of shares with sales restrictions held
Share status Quantity Peng Yixing Domestic natural person 24.70% 128,940,044 96,705,033 Not applicable 0 Lei Fenglian Domestic natural person 5.26% 27,452,696 20,589,522 Not applicable 0 Peng Haibo Domestic natural person 4.76% 24,828,700 18,621,525 Not applicable 00,000 Xiaoping Domestic natural person 2.97% 15,500,266 75,000 Not applicable 0 Liang Jinhui Domestic natural person 2.85% 14,869,400 0 Not applicable 0 Wu Jianghao Domestic natural person 1.42% 7,396,300 0 Not applicable 0 Zou Hanshu Overseas natural person 1.41% 7,359,500 0 Not applicable 0 Peng Jiulian Domestic natural person 1.35% 7,045,259 5,283,944 Not applicable 0 Wang Lan Domestic natural person 1.13% 5,904,533 4,428,400 Not applicable 0 China Construction Bank shares
Co., Ltd.-Fu
China Securities Value Trading Others 1.06% 5,540,510 0 Not applicable Type 0 open-ended index certificate
securities investment funds
Peng Yixing and Lei Fenglian are jointly the controlling shareholders and actual controllers of the company. Peng Haibo is the son of Peng Yixing and Lei Feng, the above-mentioned shareholders who are related or acting in concert. Peng Jiulian is Peng Yixing’s sister. Peng Haibo, Peng Jiulian and Peng Yixing and Lei Fenglian constitute the interpreters of concerted action. Wang Lan is Peng Jiulian's daughter and Peng Yixing's niece. The company does not know whether there are related relationships among the other shareholders mentioned above.
It is unknown whether they are persons acting in concert.
The top 10 ordinary shareholders participated in the financing. The company's shareholder, Mr. Liang Jinhui, does not hold the company's shares through ordinary securities accounts, but holds 14,869,400 shares through China Galaxy Securities Co., Ltd.'s securities business shareholder's credit transaction guaranteed securities account, holding a total of 14,869,400 shares. The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable Not applicable
Summary of the 2026 Semi-Annual Report of Jiangxi Sanxin Medical Technology Co., Ltd.
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
Whether the company has differential voting rights arrangements
□Yes No
- Changes in controlling shareholders or actual controllers
Changes in controlling shareholders during the reporting period
□Applicable Not applicable
The company's controlling shareholder did not change during the reporting period.
Changes in actual controller during the reporting period
□Applicable Not applicable
The actual controller of the company did not change during the reporting period.
- Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
The company has no preference shareholders’ shareholdings during the reporting period.
- Status of bonds existing on the date of approval of the semi-annual report
Applicable □Not applicable
(1) Basic information on bonds
bond balance
Bond name Bond abbreviation Bond code Issue date Maturity date Interest rate (10,000 yuan)
0.20% in the first year for Jiangxi Sanxin Medical Technology Co., Ltd. in the second year 0.40% in the third year 0.60%
Sanxin Convertible Bonds 123280 August 4, 2026 August 3, 2032 53,000
The issuance of specific objects can be converted into corporate bonds at 1.00% in the fourth year and 1.50% in the fifth year.
1.80% in the sixth year
(2) Financial indicators as of the end of the reporting period
Unit: 10,000 yuan
Items End of this reporting period End of previous year
Asset-liability ratio 36.43% 36.04%
Items This reporting period The same period last year
EBITDA interest coverage ratio 45.88 38.23
Summary of the 2026 Semi-Annual Report of Jiangxi Sanxin Medical Technology Co., Ltd.
3. Important matters
Overview of company operating results
During the reporting period, the company achieved operating income of 836.7226 million yuan, an increase of 9.98% over the same period last year; net profit attributable to shareholders of the listed company was 132.1159 million yuan, an increase of 14.77% over the same period last year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 121.6092 million yuan, an increase of 17.80% over the same period last year. The company's business is mainly reflected in the following areas:
Blood purification: During the reporting period, blood purification products achieved operating income of 711.11 million yuan, an increase of 13.67% over the same period last year. The operating income of such products accounted for 84.99% of the company's total revenue. During the reporting period, the company closely followed the opportunities of the centralized procurement policy, and the operating performance of its advantageous products such as hemodialyzers, hemodialysis powder, hemodialysis concentrates, and hemodialysis pipelines maintained steady growth. The operating performance of "wet membrane" dialyzers, dialysate filters, and hemodialysis filters grew rapidly and became new performance growth points.
Drug administration equipment: During the reporting period, drug administration equipment products achieved operating income of 73.8164 million yuan, a decrease of 10.43% from the same period last year. The operating income of this type of products accounted for 8.82% of the company's total revenue.
Cardiothoracic surgery: During the reporting period, cardiothoracic surgery products achieved operating income of 34.3416 million yuan, a decrease of 1.83% from the same period last year. The operating income of such products accounted for 4.10% of the company's total revenue.
Focus on quantity purchasing to improve quality and expand coverage, consolidating the dominant position of leading companies
With the normalization and institutionalization of centralized bulk purchasing, the specialized division of labor in the blood purification industry will be further strengthened, and market share will be further concentrated in large enterprises with sufficient production capacity. Leading enterprises with strong financial strength, R&D capabilities, operational capabilities, and warehousing and logistics capabilities will further increase market share, and industry concentration is expected to increase. As a leading enterprise in the field of domestic blood purification, the company has been selected for projects such as the "Twenty-Three Provinces" Hemodialysis Medical Consumables Alliance Centralized Procurement and the "Beijing-Tianjin-Hebei 3+N" Hemodialysis Consumables Alliance Centralized Procurement and other projects. Since its implementation, it has filled weak markets and consolidated major markets. While completing the agreed purchase volume, it has also obtained some incremental purchases. Before and after the centralized procurement was implemented, the company's sales of hemodialyzers and hemodialysis tubing increased significantly, and its market share further increased. The company continues to optimize its supply chain and product lines, conducts new product research and development and iterative upgrades of existing products, and launches innovative products such as "wet membrane" dialyzers to effectively solve clinical pain points, enhance patient benefits and user stickiness, and improve product profitability. In December 2025, the "Twenty-Three Provinces" Hemodialysis Medical Consumables Alliance centralized procurement started to continue the procurement work. The company's various blood purification products, including "wet membrane" dialyzers, were included in the selected product catalog, laying a solid foundation for further increasing the market share of the company's key products. Since April 30, 2026, Henan, Jiangxi, Guangdong, Hunan and other provinces have successively issued implementation notices for the continued procurement of hemodialysis medical consumables to promote the implementation of the winning results.
Products have obtained market certification in many countries, and the process of globalization has accelerated.
The company has further promoted the process of globalization strategy, and by the end of the reporting period, it had obtained overseas self-owned certificates for 88 products. By continuing to improve the global self-hosted certification system and deepening the linkage of "equipment + consumables" overseas, the company's blood purification business has further strengthened its international market layout, significantly enhanced global competitiveness, and laid a solid foundation for brand globalization. At the same time, the company pays close attention to changes in industry access and trade policies in key overseas countries and regions, strengthens in-depth cooperation with key overseas customers, and further expands overseas market territory.
Production capacity construction is expanded in an orderly manner with significant economies of scale.
In order to meet the growing market demand for hemodialysis products, realize the efficient and flexible allocation of the company's resources, reserve new production capacity for new products with broad market space, and achieve rapid expansion of new businesses such as vascular intervention, the company closely follows the market demand and relies on the advanced production technology, multi-base construction and operation management experience accumulated in the field of medical devices. It has deployed key product production capacity in multiple production bases such as Nanchang in Jiangxi, Kunming in Yunnan, and Meishan in Sichuan, giving full play to the different location advantages of each base to quickly respond to market demand. Among them, Sichuan Weilisheng, as a key fulcrum in the company's development strategy in the western region, can achieve efficient coordination of resources, drive collaborative growth of consumables business with dialysis equipment, and draw a blueprint for the innovative development of the entire blood purification industry chain. At present, Sichuan Weilisheng has hemodialysis series such as disposable hemodialyzers (dry film/wet film, Qualcomm/non-Qualcomm), hemodialysis concentrate, hemodialysis powder, disposable hemodialysis tubing, and dialysis machine disinfectant.
Summary of the 2026 Semi-Annual Report of Jiangxi Sanxin Medical Technology Co., Ltd.
The product registration certificate and the gradual release of production capacity have laid a solid foundation for the company to deeply explore the western market.
The dialysis membrane spinning line, dialyzer assembly line, and dialysate production line that have been built in the Jiangxi hemodialysis series product R&D and production base project have been put into operation one after another, providing solid production capacity guarantee for the steadily growing market demand. The company issued convertible corporate bonds to unspecified objects to raise no more than 530 million yuan, which will be used to expand the annual output of 10 million bundles of hemodialysis membranes and 10 million hemodialyzers, build a new hemodialysis pipeline production line with an annual output of 30 million sets, and supporting engineering projects. Before the raised funds are in place, the company will invest in project construction with its own funds. After the project is completed and put into operation, it will further promote the steady expansion of the company's key core product production capacity, better meet the steadily growing market demand and expand product scale efficiency, create a demonstration highland for the central medical device industry, and consolidate the company's leading position in the industry. Create an intelligent operation platform and empower high-quality industrial systems
Relying on the country's strategic layout of comprehensive digital upgrading, the company continues to promote the in-depth integration of digital technology and industry. By opening up data links, activating the value of elements, building a digital base that empowers new productivity, the company builds a strong defense line to protect people's lives and health through industrial intelligent upgrading, and steadily achieves the strategic goal of high-quality development. The company deepens the application of 5G technology, efficiently integrates internal and external data, uses the new generation of Internet information technology to empower process control, builds digital application scenarios for upstream and downstream industrial chains such as R&D, production, management, and logistics, and creates a collaborative and efficient "digital nerve center" to promote "cost reduction, efficiency improvement, and quality improvement" in all links. In 2025, the company was successfully approved to establish a provincial industrial design center, won honors such as Jiangxi Province Advanced Smart Factory and Jiangxi Province Digital Intelligence Factory, and was selected to cultivate a provincial industrial Internet platform. The level of digitalization has been comprehensively improved, and the intelligent operation system has achieved remarkable results.
The company will continue to optimize the construction of the industrial IoT ecosystem, focusing on building data monitoring and predictive maintenance models, strengthening process management and intelligent decision-making, cultivating a digital talent echelon, comprehensively improving production operation efficiency and optimizing customer delivery experience. At the same time, the company will focus on building an AI knowledge center platform, in-depth development of core scenario-based AI applications such as intelligent equipment prediction and maintenance, intelligent sales prediction, and risk warning, integrating knowledge graphs and automated processes to maximize the use of the value of knowledge assets, and systematically promote the company's intelligent transformation and upgrading process.
Share development results with shareholders and adhere to long-termism
The company has always adhered to the concepts of long-termism and value sharing, and continued to improve the long-term mechanism for shareholder returns. On the premise of complying with the principle of profit distribution and ensuring the company's normal operations and long-term development, it actively and reasonably repays the trust of investors through cash dividends and other methods, and shares the company's development results with shareholders. Since its listing in 2015, the company has implemented a total of 13 cash dividends (excluding the profit distribution plan approved by the board of directors, the same below), issued bonus shares and/or converted capital reserves to share capital 4 times, with a cumulative cash dividend amount of 651 million yuan (tax included), which is 2.83 times the net funds raised by the company's IPO. Among them: the cumulative cash dividend amount in 2025 is 157 million yuan (tax included), accounting for 59.11% of the net profit attributable to shareholders of listed companies that year. The company was successfully selected into the list of the top 100 listed companies in terms of dividend payout ratio in 2025, bringing sustained and stable investment returns to investors.
On August 21, 2026, the third meeting of the company's sixth board of directors reviewed and approved the "2026 Interim Profit Distribution Plan". The company plans to distribute a cash dividend of 1 yuan (tax included) for every 10 shares. Based on the total share capital of 521,924,275 shares as of the trading day before the disclosure date of this report after deducting the number of shares in the special securities account for repurchase, the company is expected to distribute a cash dividend of 52.19 million yuan (tax included). In addition to annual dividends, the company has implemented mid-term cash dividends for three consecutive years starting in 2024, demonstrating the company's recognition of its intrinsic value and firm confidence in future development prospects, and effectively safeguarding the interests of investors.